Plain-English translation of NCT07623798 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a new medication called can help people with multiple myeloma—a blood cancer—that has returned or stopped responding to earlier treatments. About 255 people will join this study: roughly two-thirds will receive , and one-third will receive one of the standard treatments doctors normally choose. The goal is to see if this medication works better and is safe for you.
Multiple myeloma often comes back or stops working with current treatments, leaving patients with limited options. This trial is testing whether this new medication could give people with resistant disease a more effective choice.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will either receive the new medication () or one of the standard treatments your doctor chooses, depending on which group you're randomly assigned to. You will continue treatment until your disease progresses, you experience unacceptable side effects, or you meet other stopping criteria set by the study. The study team will monitor you regularly with blood tests and scans to track how you're responding.
AI-generated summary from trial data · Oct 7, 2026 · Not medical advice
China